Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Keywords
(9)
Central Nervous System
Clinical Application
Drug Abuse
Drug Addiction
Drug Use
Drugs of Abuse
Mechanism of Action
Monoclonal Antibody
substance-related disorders
Subscribe
Academic
Publications
Inmunoterapias para las adicciones a las drogas Immunotherapies for Drug Addictions
Inmunoterapias para las adicciones a las drogas Immunotherapies for Drug Addictions,Iván D. Montoya
Edit
Inmunoterapias para las adicciones a las drogas Immunotherapies for Drug Addictions
BibTex
|
RIS
|
RefWorks
Download
Iván D. Montoya
Immunotherapies in the form of vaccines (active immunization) or monoclonal antibodies (passive immunization) appear safe and a promising treatment approaches for some substance-related disorders. The
mechanism of action
of the antibody therapy is by preventing the rapid entry of
drugs of abuse
into the central nervous system. In theory, immunotherapies could have several clinical applications. Monoclonal antibodies may be useful to treat drug overdoses and prevent the neurotoxic effects of drugs by blocking the access of drugs to the brain. Vaccines may help to prevent the development of addiction, initiate drug abstinence in those already addicted to drugs, or prevent
drug use
relapse by reducing the pharmacological effects and rewarding properties of the
drugs of abuse
on the brain. Passive immunization with monoclonal antibodies has been investigated for cocaine, methamphetamine, nicotine, and phencyclidine (PCP). Active immunization with vaccines has been studied for cocaine, heroin, methamphetamine, and nicotine. These immunotherapies seem promising therapeutic tools and are at different stages in their development before they can be approved by regulatory agencies for the treatment of substance-related disorders. The purpose of this article is to review the current immunotherapy approaches with emphasis on the risks and benefits for the treatment of these disorders.
Cumulative
Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
(
www.adicciones.es
)
References
(12)
Drug Dependence, a Chronic Medical Illness Implications for Treatment, Insurance, and Outcomes Evaluation
(
Citations: 221
)
A. Thomas McLellan
,
David C. Lewis
,
Charles P. O'Brien
,
Herbert D. Kleber
Published in 2006.
Antibodies as Pharmacokinetic and Metabolic Modifiers of Neurotoxicity
(
Citations: 5
)
S. Michael Owens
Medications development: Successes and challenges
(
Citations: 49
)
Frank Vocci
,
Walter Ling
Journal:
Pharmacology & Therapeutics - PHARMACOL THER
, vol. 108, no. 1, pp. 94-108, 2005
Drug Dependence, a Chronic Medical Illness: Implications for Treatment, Insurance, and Outcomes Evaluation
(
Citations: 356
)
A. T. McLellan
Journal:
Jama-journal of The American Medical Association - JAMA-J AM MED ASSN
, vol. 284, no. 13, pp. 1689-1695, 2000
Dopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications
(
Citations: 85
)
Nora D. Volkow
,
Joanna S. Fowler
,
Gene-Jack Wang
,
James M. Swanson
,
Frank Telang
Journal:
Archives of Neurology - ARCH NEUROL
, vol. 64, no. 11, pp. 1575-1579, 2007